Skip to main content
LALPATHLAB · Health Care · 2026-08-21

Dr. Lal PathLabs Ltd

6.5★★ GoodStrong +6.9Stage 2 · wk 11In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹1,894.2
+0.25% today
₹31,629 Cr · Large cap
About this companyHealth Care· Hospitals & Diagnostic Centres
Expand ▾

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.

Visit company website →
P/E (TTM)
51.2
Forward 39.3
Earnings Growth (YoY)
-15.4%
Revenue +16.6%
ROE
+21.5%
Profit margin +18.3%
Dividend Yield
0.87%
P/B 11.3
vs 52W High
-3.8%
₹1,307.6 lo₹1,968.4 hi
3.8% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 11
1w13w26w
Week 11 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
23.1%
200 DMA: ₹1,539.1 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.18x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 trending up · +5.7% vs MA50 +7.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #43 of 84 Stage 2 stocks in Health Care by RS.
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
55.6%
20d Δ
-7.4pp
1M return
-2.8%
3M return
+2.0%
Industry Stage-2 % · last 20 days
Ranks #6 of 15 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 27w
S2 22w
S4 14w
S2 14w
S4 16w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 8w → S2 27w → S3 7w → S4 9w → S1 2w → S2 22w → S3 12w → S4 14w → S1 10w → S2 14w → S3 11w → S4 16w → S1 5w → S2 10w current
Total tracked: 168 weeks across 14 stage runs.
1M
+12.3%
3M
+16.2%
6M
+33.3%
YTD
+33.0%
1Y
+15.5%
Scan Membership
Breakout Watch
Latest: 2026-06-10
3 appearances in last 60 days. First seen: 2024-06-10.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 11 · Vol x
2026-08-20S2
Wk 11 · Vol x
2026-08-19S2
Wk 10 · Vol x
2026-08-18S2
Wk 10 · Vol x
2026-08-17S2
Wk 10 · Vol x
2026-08-14S2
Wk 10 · Vol x
2026-08-13S2
Wk 10 · Vol x
2026-08-12S2
Wk 9 · Vol x
2026-08-11S2
Wk 9 · Vol x
2026-08-10S2
Wk 9 · Vol x
2026-08-07S2
Wk 9 · Vol x
2026-08-06S2
Wk 9 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹1,765.8
200 DMA
₹1,539.1
52W High
₹1,968.4
52W Low
₹1,307.6
5D Low
₹1,877.3
Resistance levels (recent highs)
20d High
₹1,968.4
60d High
₹1,968.4
120d High
₹1,968.4
250d High
₹1,968.4
Next resistance
+3.9%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.